What Did This CEO Just Do with Personal Shares of Puma Biotechnology (PBYI)?


Today, the President & CEO of Puma Biotechnology (PBYI), Alan Auerbach, sold shares of PBYI for $19.16K.

Following Alan Auerbach’s last PBYI Sell transaction on February 06, 2019, the stock climbed by 12.6%. In addition to Alan Auerbach, one other PBYI executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Puma Biotechnology’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $71.1 million and GAAP net loss of $30.7 million. In comparison, last year the company earned revenue of $21.6 million and had a GAAP net loss of $64.1 million. The Company has a Price to Book ratio of 45.1219. Currently, Puma Biotechnology has an average volume of 769.7K.

Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $46.67, reflecting a 19.6% upside.

The insider sentiment on Puma Biotechnology has been negative according to 26 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Alan Auerbach’s trades have generated a -67.1% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts